A review of vagus nerve stimulation as a therapeutic intervention

Rhaya L Johnson,1 Christopher G Wilson1,2 1Lawrence D Longo MD Center for Perinatal Biology, Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA; 2Department of Pediatrics, Loma Linda University, Loma Linda, CA, USA Abstract: In this review, we provide an overview of the US Food...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Johnson RL, Wilson CG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	vagus nerve stimulation pediatrics inflammation peripheral nerve stimulation Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/0ff1e94e2b0740308138ffebc9a7f61a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0ff1e94e2b0740308138ffebc9a7f61a
record_format	dspace
spelling	oai:doaj.org-article:0ff1e94e2b0740308138ffebc9a7f61a2021-12-02T00:57:18ZA review of vagus nerve stimulation as a therapeutic intervention1178-7031https://doaj.org/article/0ff1e94e2b0740308138ffebc9a7f61a2018-05-01T00:00:00Zhttps://www.dovepress.com/a-review-of-vagus-nerve-stimulation-as-a-therapeutic-intervention-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Rhaya L Johnson,1 Christopher G Wilson1,2 1Lawrence D Longo MD Center for Perinatal Biology, Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA; 2Department of Pediatrics, Loma Linda University, Loma Linda, CA, USA Abstract: In this review, we provide an overview of the US Food and Drug Administration (FDA)-approved clinical uses of vagus nerve stimulation (VNS) as well as information about the ongoing studies and preclinical research to expand the use of VNS to additional applications. VNS is currently FDA approved for therapeutic use in patients aged >12 years with drug-resistant epilepsy and depression. Recent studies of VNS in in vivo systems have shown that it has anti-inflammatory properties which has led to more preclinical research aimed at expanding VNS treatment across a wider range of inflammatory disorders. Although the signaling pathway and mechanism by which VNS affects inflammation remain unknown, VNS has shown promising results in treating chronic inflammatory disorders such as sepsis, lung injury, rheumatoid arthritis (RA), and diabetes. It is also being used to control pain in fibromyalgia and migraines. This new preclinical research shows that VNS bears the promise of being applied to a wider range of therapeutic applications. Keywords: vagus nerve stimulation, pediatrics, inflammation, peripheral nerve stimulation, autonomic circuitsJohnson RLWilson CGDove Medical Pressarticlevagus nerve stimulationpediatricsinflammationperipheral nerve stimulationPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 11, Pp 203-213 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	vagus nerve stimulation pediatrics inflammation peripheral nerve stimulation Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	vagus nerve stimulation pediatrics inflammation peripheral nerve stimulation Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Johnson RL Wilson CG A review of vagus nerve stimulation as a therapeutic intervention
description	Rhaya L Johnson,1 Christopher G Wilson1,2 1Lawrence D Longo MD Center for Perinatal Biology, Department of Basic Sciences, Loma Linda University, Loma Linda, CA, USA; 2Department of Pediatrics, Loma Linda University, Loma Linda, CA, USA Abstract: In this review, we provide an overview of the US Food and Drug Administration (FDA)-approved clinical uses of vagus nerve stimulation (VNS) as well as information about the ongoing studies and preclinical research to expand the use of VNS to additional applications. VNS is currently FDA approved for therapeutic use in patients aged >12 years with drug-resistant epilepsy and depression. Recent studies of VNS in in vivo systems have shown that it has anti-inflammatory properties which has led to more preclinical research aimed at expanding VNS treatment across a wider range of inflammatory disorders. Although the signaling pathway and mechanism by which VNS affects inflammation remain unknown, VNS has shown promising results in treating chronic inflammatory disorders such as sepsis, lung injury, rheumatoid arthritis (RA), and diabetes. It is also being used to control pain in fibromyalgia and migraines. This new preclinical research shows that VNS bears the promise of being applied to a wider range of therapeutic applications. Keywords: vagus nerve stimulation, pediatrics, inflammation, peripheral nerve stimulation, autonomic circuits
format	article
author	Johnson RL Wilson CG
author_facet	Johnson RL Wilson CG
author_sort	Johnson RL
title	A review of vagus nerve stimulation as a therapeutic intervention
title_short	A review of vagus nerve stimulation as a therapeutic intervention
title_full	A review of vagus nerve stimulation as a therapeutic intervention
title_fullStr	A review of vagus nerve stimulation as a therapeutic intervention
title_full_unstemmed	A review of vagus nerve stimulation as a therapeutic intervention
title_sort	review of vagus nerve stimulation as a therapeutic intervention
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/0ff1e94e2b0740308138ffebc9a7f61a
work_keys_str_mv	AT johnsonrl areviewofvagusnervestimulationasatherapeuticintervention AT wilsoncg areviewofvagusnervestimulationasatherapeuticintervention AT johnsonrl reviewofvagusnervestimulationasatherapeuticintervention AT wilsoncg reviewofvagusnervestimulationasatherapeuticintervention
_version_	1718403360237813760

A review of vagus nerve stimulation as a therapeutic intervention

Ejemplares similares